---
title: "TIBET PHARMA released its first-quarter performance, with a net profit attributable to the parent company of 269 million yuan, a year-on-year decrease of 13.95%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237894188.md"
description: "According to the Zhitong Finance APP, TIBET PHARMA disclosed its first-quarter report for 2025. During the reporting period, the company achieved revenue of 712 million yuan, a year-on-year increase of 1.12%; the net profit attributable to the parent company was 269 million yuan, a year-on-year decrease of 13.95%; the net profit excluding non-recurring gains and losses was 253 million yuan, a year-on-year increase of 7.90%. The basic earnings per share were 0.84 yuan"
datetime: "2025-04-28T15:16:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237894188.md)
  - [en](https://longbridge.com/en/news/237894188.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237894188.md)
---

# TIBET PHARMA released its first-quarter performance, with a net profit attributable to the parent company of 269 million yuan, a year-on-year decrease of 13.95%

According to the Zhitong Finance APP, TIBET PHARMA (600211.SH) disclosed its first-quarter report for 2025. During the reporting period, the company achieved revenue of 712 million yuan, a year-on-year increase of 1.12%; the net profit attributable to the parent company was 269 million yuan, a year-on-year decrease of 13.95%; the net profit excluding non-recurring gains and losses was 253 million yuan, a year-on-year increase of 7.90%. The basic earnings per share were 0.84 yuan

### Related Stocks

- [600211.CN](https://longbridge.com/en/quote/600211.CN.md)

## Related News & Research

- [05:20 ETThrough the America's Most Artistic Kid Competition, Colossal Raises $1.6 Million While Celebrating the Next Gen of Creative Visionaries](https://longbridge.com/en/news/287037755.md)
- [Lytix Biopharma Advances Ruxotemitide Program as Q1 2026 Results Underscore Oncology Focus](https://longbridge.com/en/news/287162474.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [China Upgrades Departure Tax Refund Policy for Foreign Visitors](https://longbridge.com/en/news/286868862.md)
- [Watkin Jones sets date for H1 2026 results and analyst webcast](https://longbridge.com/en/news/286862598.md)